心脏淀粉样变性患者起搏器植入的预测因素与结局
OBJECTIVE: We sought to investigate prevalence, incidence and prognostic implications of permanent pacemaker (PPM) implantation in patients with cardiac amyloidosis (CA), thereby identifying the predictors of time to PPM implantation.…
要点
- 心脏淀粉样变性患者起搏器植入累积发生率达20.6%。
- QRS时限和室间隔厚度是起搏器植入的独立预测因素。
- 12个月起搏器植入模型C统计量0.71,校准斜率0.98。
核心结论
- 需要起搏器的传导系统疾病是心脏淀粉样变性的常见并发症,影响高达20.6%的患者。
- QRS时限和室间隔厚度与起搏器植入独立相关。
- 所构建的12个月起搏器植入模型经校验可用于识别需要更密切随访的高风险患者。
研究设计与样本
- 分析临床、实验室和仪器检查数据,评估起搏器植入与死亡、心力衰竭或复合终点(死亡、心脏移植和心力衰竭)的关联。
主要发现
- 81例(10.3%)患者在初始评估前已植入永久起搏器。
- 中位随访21.7个月(IQR 9.6-45.2)期间,另有81例(10.3%)患者接受起搏器植入,其中18例(22.2%)为轻链淀粉样变性,63例(77.8%)为转甲状腺素蛋白淀粉样变性,中位植入时间15.6个月(IQR 4.2-40)。
- 完全性房室传导阻滞是最常见的植入指征(49.4%)。
- 起搏器植入的独立预测因素为QRS时限(HR 1.03,95%CI 1.02至1.03,p<0.001)和室间隔厚度(HR 1.1,95%CI 1.03至1.17,p=0.003)。
- 包含上述两因素的12个月起搏器植入概率模型C统计量为0.71,校准斜率为0.98。
临床怎么用
- 对心脏淀粉样变性患者应关注QRS时限和室间隔厚度,以评估起搏器植入风险。
- 可利用12个月起搏器植入模型识别高风险患者并安排更密切随访。
局限性
- 本研究为回顾性设计,纳入两家欧洲转诊中心患者,结果外推需谨慎。
- 原文未报告模型的外部验证情况。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We sought to investigate prevalence, incidence and prognostic implications of permanent pacemaker (PPM) implantation in patients with cardiac amyloidosis (CA), thereby identifying the predictors of time to PPM implantation. METHODS: Seven hundred eighty-seven patients with CA (602 men, median age 74 years, 571 transthyretin amyloidosis (ATTR), 216 light-chain amyloidosis (AL)) evaluated at two European referral centres were retrospectively included. Clinical, laboratory and instrumental data were analysed. The associations between PPM implantation and mortality, heart failure (HF) or a composite endpoint of mortality, cardiac transplantation and HF were analysed. RESULTS: 81 (10.3%) patients had a PPM before initial evaluation. Over a median follow-up time of 21.7 months (IQR 9.6-45.2), 81 (10.3%) additional patients (18 with AL (22.2%) and 63 with ATTR (77.8%)) underwent PPM implantation with a median time to implantation of 15.6 months (IQR 4.2-40), complete atrioventricular block was the most common indication (49.4%). Independent predictors of PPM implantation were QRS duration (HR 1.03, 95% CI 1.02 to 1.03, p<0.001) and interventricular septum (IVS) thickness (HR 1.1, 95% CI 1.03 to 1.17, p=0.003). The model to estimate the probability of PPM at 12 months and containing both factors showed a C-statistic of 0.71 and a calibration of slope of 0.98. CONCLUSIONS: Conduction system disease requiring PPM is a common complication in CA that affects up to 20.6% of patients. QRS duration and IVS thickness are independently associated with PPM implantation. A PPM implantation at 12 months model was devised and validated to identify patients with CA at higher risk of requiring a PPM and who require closer follow-up.
引用
- Saturi G, De Frutos F, Sguazzotti M, et al. Predictors and outcomes of pacemaker implantation in patients with cardiac amyloidosis. Heart. 2023. PMID: 37414523. doi:10.1136/heartjnl-2022-322315
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。